Antimony Trisulfide Bos Taurus Pancreas Corallium

證據等級: L5

預測適應症: 0 個

Multi-Component Botanical/Mineral Formula (Antimony Trisulfide + Saffron + 5 Components): No Repurposing Candidates Identified

One-Sentence Summary

This submission is a complex multi-component mixture comprising seven ingredients — including Antimony Trisulfide, Bovine Pancreas extract, Red Coral, Potassium Acetate, White Oak Wood, Saffron, and Umbilicus Rupestris — with no registered indication, no DrugBank ID, and no existing market authorization. The TxGNN model returned no predicted new indications for this combination, as the compound mixture could not be mapped to the knowledge graph. As a result, no clinical trial or literature evidence can be linked to this candidate at this time.

Quick Overview

Item	Content
Original Indication	Not available (no registered indication found)
Predicted New Indication	None (TxGNN returned no predictions)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; in this case, no prediction was generated
Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This candidate is an unusual multi-ingredient formula combining materials from distinctly different categories: an inorganic mineral compound (Antimony Trisulfide), an animal tissue extract (Bovine Pancreas), a marine organism skeleton (Red Coral), a common electrolyte salt (Potassium Acetate), a plant wood extract (White Oak), a culinary/medicinal spice (Saffron), and a succulent plant (Umbilicus Rupestris). Formulations of this type are more consistent with traditional, homeopathic, or compound preparation contexts than with a single pharmacological entity.

The TxGNN repurposing engine operates on a knowledge graph anchored to DrugBank IDs and established drug–disease relationships. Because no DrugBank ID exists for this mixture and the compound cannot be decomposed into individually mapped constituents within the graph, the model is unable to compute a prediction score or identify candidate indications. This is a structural data gap, not a finding of inefficacy.

It is worth noting that individual components — particularly Saffron (Crocus sativus) and Bovine Pancreatic extract — do appear in scientific literature independently. However, the combination as a whole entity lacks the standardized pharmacological profile needed for knowledge-graph-based repurposing analysis.

Safety Considerations

Please refer to the package insert for safety information. No drug interaction data, key warnings, or contraindication records were retrievable for this multi-component formula through the queried sources (DrugBank, DDI database).

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model could not generate repurposing predictions because the multi-component formula lacks a DrugBank ID and cannot be mapped to the knowledge graph. Without a pharmacological anchor, neither a prediction score nor supporting evidence can be retrieved.

To proceed, the following is needed:

Component-level decomposition: Analyse each of the 7 ingredients individually through DrugBank to determine if any single component has a DrugBank ID and existing disease associations that could anchor a prediction.
Mechanism of Action (MOA) clarification: Determine whether this formula belongs to a recognized pharmacological class (e.g., anti-inflammatory, immunomodulatory) based on its known ingredients, particularly Saffron (crocin/crocetin pathway) and Bovine Pancreas extract (enzymatic activity).
Regulatory classification: Confirm whether this formula is registered as a homeopathic preparation, traditional medicine, or dietary supplement in any jurisdiction — this determines which regulatory pathway applies.
Literature scoping for individual components: Commission a targeted PubMed search for each ingredient separately before drawing any conclusion about the combination’s therapeutic potential.
Data gap resolution (DG001, DG002): Retrieve any available package insert warnings (DG001 — Blocking severity) and MOA documentation (DG002 — High severity) before advancing to safety or efficacy evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.